Oncternal Therapeutics (NASDAQ:ONCT) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report issued on Wednesday morning. The firm issued a hold rating on the stock.

A number of other brokerages have also recently commented on ONCT. Northland Capmk cut Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. HC Wainwright reduced their price target on Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Brookline Capital Management reiterated a “hold” rating on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Finally, Northland Securities reiterated a “market perform” rating and set a $2.00 target price on shares of Oncternal Therapeutics in a research report on Thursday, September 12th. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, Oncternal Therapeutics has a consensus rating of “Hold” and a consensus price target of $20.00.

Oncternal Therapeutics Stock Down 7.2 %

Shares of ONCT opened at $0.69 on Wednesday. The business has a 50-day simple moving average of $1.29 and a two-hundred day simple moving average of $4.63. The stock has a market cap of $2.05 million, a price-to-earnings ratio of -0.06 and a beta of 1.33. Oncternal Therapeutics has a 52 week low of $0.62 and a 52 week high of $13.14.

Institutional Trading of Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 16.05% of the company’s stock.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.